The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback